There has been growing interest in the relationship between reward processing and clinical
symptoms of depression such as anhedonia (loss of interest and response to pleasurable
activities).
The aim of the study is to investigate the acute effects of a single dose of selegiline (an
irreversible monoamine oxidase B inhibitor) on reward and emotional processing in healthy
volunteers.